A Study of EMD525797 in Solid Tumor Patients in Japan

A Phase I, Open-label Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of EMD525797 After Single Dose and Repeated Dosing at Different Dose Levels in Japanese Patients With Advanced or Metastatic Solid Tumors and Progressive Diseases Following Prior Chemotherapy

The primary objectives are to assess the safety and tolerability of single and repeated doses of EMD525797, and characterize Pharmacokinetics (PK). The secondary objectives are to investigate the immunogenicity and Progressive disease (PD), and to assess the anti-tumor activity of EMD525797.

Inclusion Criteria:

• Age greater than or equal to (>=) 20 years
• Histologically or cytologically proven advanced or metastatic solid tumor
• Evidence of progressive disease after standard chemotherapy or no standard chemotherapy
• Confirmation of availability of formalin-fixed paraffin-embedded (FFPE) tumor block(s) or tissue sections
• Presence of at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 complete tumor assessment to be performed within the 30 days prior to the first EMD525797 administration
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• Estimated life expectancy of at least 3 months
• Absolute Neutrophil Count (ANC) >= 1.5 x 10^9 per liter (/Liter)
• Platelets >= 100 x 10^9/Liter
• Haemoglobin >= 9.0 gram per deciliter (g/dL) (without transfusions)
• Total bilirubin less than or equal to (<=) 1.5 x upper limit of normal (ULN)
• Aspartate transaminase (AST), alanine transaminase (ALT) less than or equal to (<=) 3 x ULN
• In subjects with hepatic metastasis, total bilirubin <= 3 x ULN, AST and ALT <= 5 x ULN
• Prothrombin time (PT), prothrombin time/international normalized ratio (PT/INR), and activated partial thromboplastin time (APTT) within normal limits
• Creatinine clearance >= 50 milliliter per minute (mL/min)

Other protocol defined inclusion criteria could also apply

Exclusion Criteria:

• Previous treatment with anti-integrin therapy
• Radiotherapy to bone lesions, systemic surgery, orthopedic surgery (all within the 4 week prior to treatment with EMD525797), clinically significant unhealed wound, or unrecovered bone fracture
• Chronic doses of oral steroids, defined as >= 10 milligram of prednisone equivalents per day
• Confirmed or clinically suspected brain or leptomeningeal metastases
• Known hypersensitivity to EMD525797 or its excipients
• History of allergic reactions to other monoclonal antibody therapy
• Antibody treatment within the past 8 weeks or chemotherapy within the 4 weeks prior to treatment with EMD525797
• Uncontrolled diabetes
• Uncontrolled hypertension defined as systolic blood pressure >= 160 millimeter of mercury (mmHg) and/or diastolic blood pressure >= 100 millimeter of mercury (mmHg) under resting conditions
• Autoimmune diseases
• Current history of chronic daily acetylsalicylic acid (ASS) therapy (ASS at doses <=100 mg is permitted)
• Bleeding disorders;
• History of thromboembolic events (history of superficial thrombophlebitis is not an exclusion
• Anticoagulants within the past 10 days prior to the first treatment and during treatment period
• Severe peripheral vascular disease or ulceration
• Unstable angina pectoris, or myocardial infarction or other severe heart diseases within the past 6 months before treatment with EMD 525797
• Clinical significant abnormal ECG at screening
• Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
• Known HIV infection, active or chronic carrier of hepatitis B virus (HBV antigen positive or HBV DNA positive) or hepatitis C virus (HCV antibody positive)

Other protocol defined exclusion criteria could also apply